Mati Fridkin
Home Page of Prof. Matityahu (Mati) Fridkin

The Lester B. Pearson Professorial Chair
of Protein Research

The Weizmann Institute of Science
76100 Rehovot, Israel
telephone: +972 (8) 934-2505, 2508 
e-mail: mati.fridkin@weizmann.ac.il


Members of the group:

Aviva Kapitkowsky, Ph.D. aviva.kapitkovsky@weizmann.ac.il
Sarah Rubinraut, Ph.D. Extension 2977
Shai Rahimipourshai.rahimipour@weizmann.ac.il
Haim Tsubery haim.tsubery@weizmann.ac.il
Doudy Dangoordoudy.dangoor@weizmann.ac.il
Hailin Zhenghailin.zheng@weizmann.ac.il


Research projects

Chemical, Biological and Clinical Studies of Modulatory Peptides

Proteolysis of acute-phase proteins leads to generation of immunomodulatory and anti-inflammatory peptides. The possible involvement of these compounds and the parent proteins in the body's defense mechanisms are being investigated. Studies are directed toward isolation of bioactive peptides from physiological sources, structural elucidation, synthesis, scope and mode of function, structure-function relationships, antibacterial and antitumor activities, potential clinical implications, diagnoses of human diseases, and application to the preparation of synthetic vaccines. The investigation of biosynthesis, metabolism, application to human therapy, total synthesis, and structure-function studies of neuropeptides are in progress. Mechanisms of microbial killing, development of potent related drugs and isolation of novel antibacterial-antiviral peptides from natural sources are also being investigated.



Click here for list of all publications since 2000 (including DOIs) [Submit additions and corrections]

Selected publications

S Rahimipour, N. Ben-Aroya, K. Ziv, A. Chen, M. Fridkin, and Y. Koch, Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues J MED CHEM 46 (19): 3965-3974 SEP 11 2003 [read online]

Y Shechter, H. Tsubery, and M. Fridkin, Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats BIOCHEM BIOPH RES CO 307 (2): 315-321 JUL 25 2003 [read online]

S Hindi, D. P. Grossman, I. Goldwaser, Y. Shechter, and M. Fridkin, Potentiating vanadium-evoked glucose metabolism by novel hydroxamate derivatives LETT PEPT SCI 9 (6): 235-254 2002

Y Shechter, H. Tsubery, and M. Fridkin, [2-Sulfo-9-fluorenylmethoxycarbonyl](3)-exendin-4 - a long-acting glucose-lowering prodrug BIOCHEM BIOPH RES CO 305 (2): 386-391 MAY 30 2003 [read online]

E Katchalski-Katzir, R. Kasher, M. Balass, T. Scherf, M. Harel, M. Fridkin, J. L. Sussman, and S. Fuchs, Design and synthesis of peptides that bind alpha-bungarotoxin with high affinity and mimic the three-dimensional structure of the binding-site of acetylcholine receptor BIOPHYS CHEM 100 (1-3): 293-305 Sp. Iss. SI 2003 [read online]

Y Shechter, I. Goldwaser, M. Mironchik, M. Fridkin, and D. Gefel, Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes COORDIN CHEM REV 237 (1-2): 3-11 FEB 2003 [read online]

S Rahimipour, C. Palivan, F. Barbosa, I. Bilkis, Y. Koch, L. Weiner, M. Fridkin, Y. Mazur, and G. Gescheidt, Chemical and photochemical electron transfer of new helianthrone derivatives: Aspects of their photodynamic activity J AM CHEM SOC 125 (5): 1376-1384 FEB 5 2003 [read online]

M Trebicz-Geffen, Z. Nevo, Z. Evron, N. Posternak, T. Glaser, M. Fridkin, Y. Kollander, and D. Robinson, The short-lived exostosis induced surgically versus the lasting genetic hereditary multiple exostoses EXP MOL PATHOL 74 (1): 40-48 FEB 2003

A Levy, R. Gal, R. Granoth, Z. Dreznik, M. Fridkin, and I. Gozes, In vitro and in vivo treatment of colon cancer by VIP antagonists REGUL PEPTIDES 109 (1-3): 127-133 NOV 15 2002 [read online]

I Gozes, S. Furman, I. Vulih, Y. Segal-Ruder, M. Fridkin, and D. E. Brenneman, VIP, novel proteins and peptide-mediated neuronal survival EUR NEUROPSYCHOPHARM 12: S145-S146 Suppl. 3 OCT 2002

H Tsubery, I. Ofek, S. Cohen, M. Eisenstein, Fridkin M Modulation of the hydrophobic domain of polymyxin B nonapeptide: Effect on outer-membrane permeabilization and lipopolysaccharide neutralization MOL PHARMACOL 62 (5): 1036-1042 NOV 2002

Y Wollman, S. Blumberg, A. Spungin, D. E. Brenneman, M. Fridkin, J. Wollman, A. Iaina, and I. Gozes, The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase REGUL PEPTIDES 108 (2-3): 175-177 OCT 15 2002 [read online]

RA Steingart, E. Heldenberg, A. Pinhasov, D. E. Brenneman, M. Fridkin, and I. Gozes, A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes LIFE SCI 71 (21): 2543-2552 OCT 11 2002 [read online]

Y Shechter, H. Tsubery, and M. Fridkin, N-[(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C-1 is a long-acting prodrug derivative J MED CHEM 45 (19): 4264-4270 SEP 12 2002 [read online]

L Carmon, I. Bobilev-Priel, B. Brenner, D. Bobilev, A. Paz, E. Bar-Haim, B. Tirosh, T. Klein, M. Fridkin, F. Lemonnier, E. Tzehoval, and L. Eisenbach, Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D-b-beta 2m transgenic mice J CLIN INVEST 110 (4): 453-462 AUG 2002 [read online]

M Blank, I. Krause, M. Fridkin, N. Keller, J. Kopolovic, I. Goldberg, and Y. Shoenfeld, Molecular mimicry between microbial pathogens and beta2GP1: The induction of experimental APS. CLIN IMMUNOL 103 (3): 400 Part 2 Suppl. S JUN 2002

RR Leker, A. Teichner, N. Grigoriadis, H. Ovadia, D. E. Brenneman, M. Fridkin, E. Giladi, J. Romano, and I. Gozes, NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death STROKE 33 (4): 1085-1092 APR 2002 [read online]

TW Moody, R. T. Jensen, M. Fridkin, and I. Gozes, (N-stearyl, Norleucine(17))VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist J MOL NEUROSCI 18 (1-2): 29-35 FEB-APR 2002

M Blank, I. Krause, M. Fridkin, N. Keller, J. Kopolovic, I. Goldberg, A. Tobar, and Y. Shoenfeld, Bacterial induction of autoantibodies to beta 2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome J CLIN INVEST 109 (6): 797-804 MAR 2002 [read online]

A Sharma, J. Walters, Y. Gozes, M. Fridkin, D. Brenneman, I. Gozes, and T. W. Moody, A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells J MOL NEUROSCI 17 (3): 331-339 DEC 2001

S Urieli-Shoval, G. Shubinsky, R. P. Linke, M. Fridkin, I. Tabi, Matzner Y Adhesion of human platelets to serum amyloid A BLOOD 99 (4): 1224-1229 FEB 15 2002 [read online]

D Pelled, T. Raveh, C. Riebeling, M. Fridkin, H. Berissi, A. H. Futerman, and A. Kimchi, Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons J BIOL CHEM 277 (3): 1957-1961 JAN 18 2002 [read online]

R Xu, J. Abramson, M. Fridkin, and I. Pecht, SH2 domain-containing inositol polyphosphate 5 '-phosphatase is the main mediator of the inhibitory action of the mast cell function-associated antigen J IMMUNOL 167 (11): 6394-6402 DEC 1 2001

M Harel, R. Kasher, A. Nicolas, J. M. Guss, M. Balass, M. Fridkin, A. B. Smit, K. Brejc, T. K. Sixma, E. Katchalski-Katzir, J. L. Sussman, and S. Fuchs, The binding site of acetylcholine receptor as visualized in the X-ray structure of a complex between alpha-bungarotoxin and a mimotope peptide NEURON 32 (2): 265-275 OCT 25 2001 [read online] (Link to ScienceDirect, no DOI available yet)

S Rahimipour, N. Ben-Aroya, M. Fridkin, and Y. Koch, Design, synthesis, and evaluation of a long-acting, potent analogue of gonadotropin-releasing hormone J MED CHEM 44 (22): 3645-3652 OCT 25 2001 [read online]

Y Schechter, I. Goldwaser, I. Lavon, E. Gershonov, B. Mester, M. Mironchik, L. P. Patt, and M. Fridkin, A new approach for prolonging the half-life of peptides, proteins and low-molecular-weight drugs in vivo DRUG FUTURE 26 (7): 669-676 JUL 2001

E Gelber, R. Granoth, M. Fridkin, Z. Dreznik, D. E. Brenneman, T. W. Moody, and I. Gozes, A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines CANCER 92 (8): 2172-2180 OCT 15 2001 [read online]

H Tsubery, I. Ofek, S. Cohen, and M. Fridkin, N-terminal modifications of Polymyxin B nonapeptide and their effect on antibacterial activity PEPTIDES 22 (10): 1675-1681 OCT 2001

TW Moody, J. Leyton, D. Chan, D. C. Brenneman, M. Fridkin, E. Gelber, A. Levy, and I. Gozes, VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells BREAST CANCER RES TR 68 (1): 55-64 JUL 2001

S Rahimipour, C. Palivan, D. Freeman, F. Barbosa, M. Fridkin, L. Weiner, Y. Mazur, and G. Gescheidt, Hypericin derivatives: Substituent effects on radical-anion formation PHOTOCHEM PHOTOBIOL 74 (2): 149-156 AUG 2001

S Rahimipour, I. Bilkis, V. Peron, G. Gescheidt, F. Barbosa, Y. Mazur, Y. Koch, L. Weiner, and M. Fridkin, Generation of free radicals by emodic acid and its [D-Lys(6)]GnRH-conjugate PHOTOCHEM PHOTOBIOL 74 (2): 226-236 AUG 2001

M Katz, S. Kolushev, H. Tsubery, M. Fridkin, and R. Jelinek, Biological and chemical properties of lipid/polydiacetylene colorimetric vesicle biosensors. BIOCHEMISTRY-US 40 (29): 204 JUL 24 2001 [read online]

O Ashur-Fabian, E. Giladi, S. Furman, R. A. Steingart, Y. Wollman, M. Fridkin, D. E. Brenneman, and I. Gozes, Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures NEUROSCI LETT 307 (3): 167-170 JUL 20 2001 [read online]

T Scherf, R. Kasher, M. Balass, M. Fridkin, S. Fuchs, and E. Katchalski-Katzir, A beta-hairpin structure in a 13-mer peptide that binds alpha-bungarotoxin with high affinity and neutralizes its toxicity P NATL ACAD SCI USA 98 (12): 6629-6634 JUN 5 2001 [read online] D Tisch-Idelson, M. Fridkin, F. Wientjes, and I. Aviram, Structure-function relationship in the interaction of mastoparan analogs with neutrophil NADPH oxidase BIOCHEM PHARMACOL 61 (9): 1063-1071 MAY 1 2001 [read online] R Kasher, M. Balass, T. Scherf, M. Fridkin, S. Fuchs, and E. Katchalski-Katzir, Design and synthesis of peptides that bind alpha-bungarotoxin with high affinity CHEM BIOL 8 (2): 147-155 FEB 2001 [read online] RA Steingart, B. Solomon, D. E. Brenneman, M. Fridkin, and I. Gozes, VIP and peptides related to activity-dependent neurotropic factor protect PC12 cells against oxidative stress J MOL NEUROSCI 15 (3): 137-145 DEC 2000 E Sigalov, M. Fridkin, D. E. Brenneman, and I. Gozes, VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells J MOL NEUROSCI 15 (3): 147-154 DEC 2000 Y Shechter, L. Preciado-Patt, G. Schreiber, and M. Fridkin, Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)(7)-interferon-alpha 2 P NATL ACAD SCI USA 98 (3): 1212-1217 JAN 30 2001 [read online]


H. Tsubery, I. Ofek, S. Cohen and M. Fridkin, N-terminal modifications of polymyxin B nonapeptide and their effect on antibacterial activity. Peptides In press (2001).

S. Rahimipour, N. Ben-Aroya, M. Fridkin and Y. Koch, Design, synthesis and evaluation of a long-acting, potent analog of gonadotropin-releasing hormone. J. Med. Chem. In press (2001).

Y. Shechter, I. Goldwaser, I. Lavon, E. Gershonov, B. Mester, M. Mironchik, L. Preciado-Patt and M. Fridkin, A new approach for prolonging the half-life of peptides, proteins and low-molecular-weight drugs in vivo. Drugs of the Future, 26, in press (2001).

R. Kasher, M. Balass, T. Scherf, M. Fridkin, S. Fuchs and E. Katchalski-Katzir, Design and synthesis of peptides that bind a-bungarotoxin with high affinity. Chem. Biol. 8, 147-155 (2001).[read online]

D. Tisch-Idelson, M. Fridkin, F. Wientjes and I. Aviram, Structure-function relationship in the interaction of mastoparan analogs with neutrophil NADPH oxidase. Biochem. Pharmacol. 61, 1063-1071 (2001). [read online]

O. Ashur-Fabian, E. Giladi, S. Furman, R.A. Steingart, Y. Wollman, M. Fridkin, D.E. Brenneman and I. Gozes, Vasoactive intestinal peptide and related molecules induce nitrite accumulation in extracellular milieu of rat cerebral cortical cultures. Neurosci. Lett. 307, 167-170 (2001). [Read online]

S. Rahimipour, I. Bilkis, V. Pˇron, G. Gescheidt, F. Barbosa, Y. Mazur, Y. Koch, M. Fridkin and L. Weiner, Generation of free radicals by emodin and its [D-Lys6]GhRH conjugates. Photochem. Photobiol. 74, 226 (2001). [Read abstract; Read PDF]

T. Scherf, R. Kasher, M. Balass, M. Fridkin, S. Fuchs and E. Katchalski-Katzir, A beta-hairpin structure in a 13-mer peptide that binds alpha-bungarotoxin with high affinity and neutralizes its toxicity. Proc. Natl. Acad. Sci. USA 98, 6629-6634 (2001). [read online]

S. Rahimipour, C. Palivan, D. Freeman, F. Barbosa, M. Fridkin, L. Weiner, Y. Mazur and G. Gescheidt, Hypericin derivatives: substituent effects on radical-anion formation. Photochem. Photobiol. 74, 149 (2001). [View abstract; View PDF]

Y. Shechter, L. Preciado-Patt, G. Schreiber and M. Fridkin. Prolonging the half-life of human interferon-alpha-2 in circulation: design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7-interferon-alpha-2). Proc. Natl. Acad. Sci. USA 98, 1212 (2001).[read online]

B. Tirosh, M. Fridkin, E. Tzehoval, E. Vadai, F.A. Lemonnier and L. Eisenbach. Antigenicity and immunogenicity of an intracellular delivery system of major hisotcompatibility complex class I epitopes that bypasses proteasome processing. J. Immunother. 23, 622 (2000).[read abstract]

N. Brosh, H. Zinger, M. Fridkin and E. Mozes. A peptide based on the sequence of the CDR3 of a murine anti-DNA mAb is a better modulator of experimental SLE than its single amino acid-substituted analogs. Cell. Immunol. 205, 52 (2000).[read online]

R. Kasher, M. Balass, T. Scherf, M. Fridkin, S. Fuchs and E. Katchalski-Katzir. Design and synthesis of peptides that bind alpha-bungarotoxin with high affinity. Chem. Biol. 8, 147 (2000).

E. Eilat, M. Fridkin and E Mozes. A peptide based on the CDR1 of a pathogenic anti-DNA antibody is more efficient than its analogs in inhibiting autoreactive T cells. Immunobiol. 202, 38 (2000).[read abstract]

I. Goldwaser, D. Gefel, E. Gershonov, M. Fridkin and Y. Shechter. Insulin-like effects of vanadium: basic and clinical implications. J. Inorg. Biochem. 80, 21 (2000).[read abstract]

M. Dayan, R. Segal, Z. Sthoeger, A. Waisman, N. Brosh, O. Elkayam , E. Eilat, M. Fridkin and E. Mozes. Immune response of SLE patients to peptides based on the complementarity determining regions (CDR) of a pathogenic anti-DNA monoclonal antibody. J. Clin. Immunol. 20, 18 (2000).[read online]

N. Brosh, M. Dayan, M. Fridkin and E. Mozes. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is a dominant T cell eptiope also in (NZBxNZW)F1 lupus-prone mice. Immunol. Lett. 72, 61 (2000).[read online]

H. Zia, J. Leyton, M. Casibang, V. Hau, D. Brenneman, M. Fridkin, I. Gozes and T.W. Moody. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. Life Sci. 66, 379 (2000).[read online]

D. Yahalom, Y. Koch, N. Ben-Aroya and M. Fridkin. Hexapeptide and cyclic pentapeptide endothelin antagonists directly activate pituitary gonadotropin-releasing hormone receptors. Mol. Pharmacol. 57, 718 (2000).[read online]

D. Yahalom, S. Rahimipour, Y. Koch, N. Ben-Aroya and M. Fridkin. Structure-activity studies of reduced-size gonadotropin-releasing hormone antgonists derived from the sequence of an endothelin antagonist. J. Med. Chem. 43, 2824 (2000).[read online]

D. Yahalom, S. Rahimipour, Y. Koch, N. Ben-Aroya and M. Fridkin. Design and synthesis of potent hexapeptide and heptapeptide gonadotropin-releasing hormone antgonists by truncation of a decapeptide analog sequence. J. Med. Chem. 43, 2831 (2000).[read online]

E.J. Yavin, L. Preciado-Patt, O. Rosen, M. Yaron, R.D. Seussmuth, D. Levartowsky, G. Jung, O. Lider and M. Fridkin. Serum amyloid A-derived peptides, present in human rheumatic synovial fluids, induce the secretion of interferon-gamma by human CD4+ T-lymphocytes. FEBS Lett. 472, 259 (2000).[read online]

E. Gerhsonov, I. Goldwasser, M. Fridkin and Y. Shechter. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation and anlaysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl]3-insulin. J. Med. Chem. 43, 2530 (2000).[read online]

S. Qian, N. Sekar, I. Goldwasser, E. Gershonov, M. Fridkin and Y. Shechter. Vanadate restores glucose 6-phosphate in diabetic rats; a mechanism to enhance glucose metabolism. Am. J. Physiol Endocrinol Metab. 279, 403 (2000).[read online]

R. Granoth, M. Fridkin, S. Rubinraut and I. Gozes. VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. FEBS Lett. 475, 71 (2000).[read online]

R. Granoth, M. Fridkin and I. Gozes. VIP and the potent analog, stearyl-Nle17-VIP, induce proliferation of keratinocytes. FEBS Lett. 475, 78 (2000).[read online]

H. Tsubery, I. Ofek, S. Cohen and M. Fridkin. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria. J. Med. Chem. 43, 3085 (2000).[read online]

H. Tsubery, I. Ofek, S. Cohen and M. Fridkin. The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide. Biochemistry, 39, 11837 (2000).[read online]

I. Goldwasser, S. Qian, E. Gerhsonov, M. Fridkin and Y. Shechter. Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishling criteria for optimal chelators. Mol. Pharmacol. 58, 738 (2000).[read online]

H. Tsubery, I. Ofek, S. Cohen and M. Fridkin. Structure-activity relationship study of polymyxin B nonapeptide. In: The Biology and Pathology of Innate Immunity Mechanisms. (Y. Keisari and I. Ofek, Eds.) Kluwer Academic/Plenum Publishers, pp. 219-222 (2000).

S. Rahimipour, G. Gescheidt, Y. Mazur, L. Weiner, Y. Koch and M. Fridkin. Cytotoxic derivatives of luteinizing hormone-release hormone (LHRH): synthesis and evaluation. In: Peptides for the New Millennium. Proc. 16th American Peptide Symposium, 1999, Minneapolis, Minnesota, USA (G.B. Fields, J.P. Tam, G. Barany, Eds.) Kluwer Academic Publishers, Dordrecht, pp. 238-239 (2000).

H. Tsubery, I. Ofek, S. Cohen and M. Fridkin. Biological activities of polymyxin B nonapeptide analogs. In: Peptides for the New Millennium. Proc. 16th American Peptide Symposium, 1999, Minneapolis, Minnesota, USA (G.B. Fields, J.P. Tam, G. Barany, Eds.) Kluwer Academic Publishers, Dordrecht, pp. 742-743 (2000).

R. Philosof-Oppenheimer, C.S. Hampe, K. Schlessinger, M. Fridkin and I. Pecht. An immunoreceptor tyrosine-based inhibitory motif, with serine at site Y-2, binds SH2-domain containing phosphatases. Eur. J. Biochem. 267, 703 (2000).[read html file][read pdf file]

D. Offen, Y. Sherki, E. Melamed, M. Fridkin, D.E. Brenneman and I. Gozes. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854, 257 (2000).[read online]

L. Preciado-Patt, R. Hershkovitz, O. Lider, S. Feiertag,G. Jung and M. Fridkin. A study of extracellular matrix-cell adhesion peptidic epitopes related to human serum amyloid A (SAA). Lett. in Pept. Sci. 6, 99 (1999).[read online]

E.J. Yavin and M. Fridkin. Peptides derived from human C-reactive protein inhibit hypochlorous acid production by human neutrophil myeloperoxidase. In: Peptides 1998 (Sandor Bajusz and Ference Hudecz, Eds.) Akademiai Kiado, Budapest, pp. 848-849 (1999).

E. Gershonov, Y. Shechter and M. Fridkin. 9-Fluorenylmethoxycarbonyl-insulin. Potential approach for prolonged-acting insulin. In: Peptides 1998 (Sandor Bajusz and Ference Hudecz, Eds.) Akademiai Kiado, Budapest, pp.852-853 (1999).

D. Yahalom, Y. Koch, N. Ben-Aroya and M. Fridkin. Synthesis and bioactivity of fatty acid-conjugated GnRH derivatives. Life Sci. 64, 1543 (1999).[read online]

I. Gozes, O. Perl, E. Giladi, O. Ashur-Fabian, S. Rubinraut and M. Fridkin. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. USA 96, 4143 (1999).[read online]

S. Koenen-Waisman, A. Cohen, M. Fridkin and I.R. Cohen. Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococal infection. J. Infect. Diseases 179, 403 (1999).[read online]

P. Gressens, L. Besse, P. Robberecht, I. Gozes, M. Fridkin and P. Evard. Neuroprotection of the developing brain by systemic adminstration of vasoactive intestinal peptide derivatives. J. Pharmacol. Exp. Therapy 288, 1207 (1999).[read online]

D. Yahalom, Y. Koch, N. Ben-Aroya and M. Fridkin. Design and synthesis of novel GnRH endothelin chimeras. In: Peptides, Frontiers of Peptide Science (J.P. Tam and P.T.P. Kaumaya, Eds.), Kluwer Academic Publishers, Dordrecht, pp. 621-622 (1999).

L. Preciado-Patt, R. Shainkin-Kestenbaum and M. Fridkin. Serum amyloid A and its related peptides modulate endothelial cells proliferation and prostaglandin I2 production. In: Peptides, Frontiers of Peptide Science (J.P. Tam and P.T.P. Kaumaya, Eds.), Kluwer Academic Publishers, Dordrecht, pp. 745-746 (1999).

R. Granoth, M. Fridkin and I. Gozes. Neuropeptides and skin function: VIP and stearyl-[Nle17]VIP effect on HaCat cells. In: Peptides, Frontiers of Peptide Science (J.P. Tam and P.T.P. Kaumaya, Eds.), Kluwer Academic Publishers, Dordrecht, pp. 749-750 (1999).

E. Gershonov, Y. Shechter and M. Fridkin. New concept for long-acting insulin: spontaneous conversion of inactive modified-insulin to the active hormone in circulation; 9-fluorenylmethoxycarbonyl (Fmoc) derivative of insulin. Diabetes 48, 1437 (1999).[read abstract][read pdf file]

M. Blank, Y. Shoenfeld, S. Cabilly, Y. Heldman, M. Fridkin and E. Katchalski-Katzir. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc. Natl. Acad. Sci. USA 96, 5164 (1999).[read online]

I. Goldwasser, J. Li, E. Gershonov, M. Armoni, E. Karnieli, M. Fridkin and Y. Shechter. L-glutamic acid gamma-mono-hydroxamate: A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. J. Biol. Chem. 274, 26617 (1999).[read online]

O. Ashur-Fabian, O. Perl, G. Lilling, M. Fridkin and I. Gozes. SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides 20, 629 (1999).[read online]

B. Tirosh, K. el-Shami, N. Vaisman, L. Carmon, E. Bar-Haim, E. Vadai, M. Feldman, M. Fridkin and L. Eisenbach. Immunogenicity of H-2Kb-low affinity, high affinity and covalently-bound peptides in anti-tumor vaccination. Immunol. Lett. 70, 21 (1999).[read online]

K. el-Shami,, B. Tirosh, E. Bar-Haim, L. Carmon, E. Vadai, M. Fridkin, M. Feldman and L. Eisenbach. MHC class 1-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominent CTL epitope. Eur. J. Immunol. 29, 3295 (1999).[read online]

M. Yaniv, D. Dabbi, H. Amir, S. Cohen, M. Mozes, H. Tsuberi, M. Fridkin, S. Dekel and I. Ofek. Prolonged leaching time of peptide antibiotics from acrylic bone cement. Clin. Orthopaedics and Related Res. 363, 232 (1999).

H.-Y. Wang, X. Jiang, I. Gozes, M. Fridkin, D.E. Brenneman and D. Ganea. Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regulatory Peptides 84, 55 (1999).[read online]

I. Gozes, M. Fridkin, J.M. Hill and D.E. Brenneman. Pharmaceutical VIP: prospects and problems. Curr. Med. Chem. 6, 1019 (1999).[read abstract]

I. Gozes, O. Perl, R. Zamostiano, S. Rubinraut, M. Fridkin, L. Shochat and L.M. Lewin. Multiple actions of anhybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Ann. N.Y. Acad. Sci. 865, 266 (1998).

Y. Katz-Levy, M. Dayan, I. Wirguin, M. Fridkin, M. Sela and E. Moses. Single amino acid analogs of a myasthenogenic peptide modulate specific T-cell responses and prevent the induction of experimental autoimmune myasthenia gravis. J. Neuroimmunology 85, 78 (1998).

Y. Shechter, G. Eldberg, A. Shisheva, D. Gefel, N. Sekar, S. Qian, R. Bruck, E. Gershonov, D.C. Crans, Y. Goldwasser, M. Fridkin and J. Li. Insulin-like effects of vanadium; reviewing in vivo and in vitro studies and mechanisms of action. In: Vanadium Compounds, Chemistry, Biochemistry and Therapeutic Application (A.S. Trancey and D.C. Crans, Eds.) ACS Symposium Series 711, American Chemical Society, Washington DC, Chapter 24, pp. 208-315 (1998).

E.J. Yavin, L. Preciado-Patt, H. Berger and M. Fridkin. On the puzzle of the acute phase reactants and serum amyloid A. In: Peptide Science - Present and Future (Y. Shimonishi, Ed.), Kluwer Academic Publ., Great Britain, pp. 819-822 (1998)

D. Leibovitz, M. Fridkin, N. Ben-Aroya and Y. Koch. Degradation of gonadotropin-releasing hormone (GnRH) by pituitary enzymes is modulated by desensitization. Isr. J. Obstet & Gynecol. 8, 151 (1998).

D.E. Brenneman, J. Hauser, E. Neal, S. Rubinraut, M. Fridkin, A. Davidson and I. Gozes. Activity-dependent neurotropic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharm. Exper. Therap. 285, 619 (1998).

V. Zupan, J.M. Hill, D.E. Brenneman, I. Gozes, M. Fridkin, P. Robberecht, P. Evrard and P. Gressens. Involvement of pituitary adenylae cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis J. Neurochem. 70, 2165 (1998).

L. Eisenbach, O. Mandelboim, R. Bar-Haim, L. Carmon, H. Copow, K. El-Shami, A. Paz, D. Popovic, E. Vadai, E. Tzehoval, M. Feldman and M. Fridkin. Tumor-associaed antigen peptides as anti-metastatic vaccines. Lett. in Pept. Sci. 5, 323 (1998)

L. Preciado-Patt, L. Cahalon, R. Hershkovitz, O. Lider, M. Pras and M. Fridkin. Serum amyloid A complexed with extracellular matrix induces the secretion of tumor necrosis factor-a by human T-lymphocytes. Lett. in Pept. Sci. 5, 349 (1998)

S. Rahimipour, L. Weiner, P.B. Shrestha-Dawadi, S. Bittner, Y. Koch and M. Fridkin. Cytotoxic peptides: Naphthoquinonyl derivatives of luteinizing-hormone-releasing hormone. Lett. in Pept. Sci. 5, 421 (1998).

A. Ariel, E.J. Yavin, R. Hershkovitz, A. Avron, S. Franitza, I. Hardan, L. Cahalon, M. Fridkin and O. Lider. IL-2 induces T-cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. J. Immunol. 161, 2465 (1998)

P. Landsmann, N. Borochov, M. Pontet, M. Pras and M. Fridkin. Self-association of human serum amyloid P (hSAP) is mediated by heparin and by SAP-derived peptides. In: Peptide 1996 (Ramage, R. and Epton, R., Eds). Mayflower Scientific Ltd., Kingswinford, England, pp. 565-566 (1998).

E.J. Yavin, M. Eisenstein, L. Yan, D.M. Desiderio and M. Fridkin. Peptides derived from the sequence of human C-reactive protein inhibit the enzymatic activity of human leukocyte elastase. In: Peptide 1996 (Ramage, R. and Epton, R., Eds). Mayflower Scientific Ltd., Kingswinford, England, pp. 929-930 (1998).

M.E. Gatt, S. Urieli-Shoval, L. Preciado-Patt, M. Fridkin, S. Calco, Y. Azar and Y. Matzner, Effect of serun amyloid A on selected in vitro functions of isolated human neutrophils. Lab. Clin. Med. 132, 414 (1998).

M. Delgado, E.J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D.E. Brenneman, R.P. Gomaritz and D. Ganea, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor a transcriptional activation by regulatory nuclear factor KB and cAMP response element-binding protein /CJun. J. Biol. Chem. 273, 31427 (1998).[read online]

E.J. Yavin and M. Fridkin, Peptides derived from human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and Cathepsin G: Use of overlapping peptide sequences to identify a unique inhibitor. J. Pept. Res. 51, 282 (1998).

R. Shainkin-Kestenbaum, S. Zimlichman, M. Lis, C. Lidor, M. Pomerantz, A. Knyszynski, L. Preciado-Patt and M. Fridkin. Effect of serum amyloid A, HDL-apolipoprotein, on endothelial cell proliferation. Implication of an enygmatic protein to atherosclerosis. Biomed. Pept. Prot. Nucleic Acids 2, 79 (1997).

O. Mandelboim, E. Bar-Haim, E. Vadai, M. Fridkin and L. Eisenbach. Identification of shared tumor-associated antigen peptides between two spontaneous lung-carcinomas. J. Immunol.159, 6040 (1997).

E.J Yavin, M. Eisenstein and M. Fridkin. Binding pockets on the surface of human leukocyte elastase and human cathepsin G. Implications to the design of inhibitors derived from human C-reactive protein. Biomed. Pept. Prot. Nucleic Acids 2, 71 (1997).

R. Hershkovitz, L. Preciado-Patt, O. Lider, M. Fridkin, J. Dastych, D.D. Metcalfe and Y.A. Mekori. Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Am. J. Physiol: Cell Physiol. 42, 179 (1997).

I. Gozes, M. Bachar, A. Bardea, A. Davidson, S. Rubinraut, M. Fridkin and E. Giladi. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimer's disease. J. Neurobiol. 33, 329 (1997).

I. Gozes, A. Bardea, M. Bachar, O. Pearl, A. Reshef, R. Zomostiano, A. Davidson, S. Rubinraut, E. Giladi, M. Fridkin and D.E. Brenneman. Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Ann. N.Y. Acad. Sci. 814, 161 (1997)

P. Gressens, S. Marret, J.M. Hill, D.E. Brenneman, I. Gozes, M. Fridkin. and P. Evrard. Vasoactive intestinal peptide protects against excitotoxic hypoxic-like death in the murine developing brain. J. Clin. Invest. 100, 390 (1997).

E.J. Yavin, L. Yan, D.M. Desiderio, M. Pontet and M. Fridkin. Inhibition of human leukocyte elastase and cathepsin G by extended human C-reactive protein derived peptides and subunits. Lett. Pept. Sci. 4, 157 (1997).

J.R. Pisegna, T. Leyton, T. Coelho, T. Hida, S. Jakowlew, M. Birrer, M. Fridkin, I. Gozes and T.W. Moody. PACAP hybrid antagonizes PACAP splice variants. Life Sci. 61, 631 (1997).

J.Y. Wu, K.A. Henins, P. Gressens, I. Gozes, M. Fridkin, D.E. Brenneman and J.M. Hill. Prenatal blockade of vasoactive intestinal peptide delays developmental milestones in the neonatal mouse. Peptides 18, 1131 (1997).

E. Rajnavolgyi, A. Horvath, P. Gogolak, G.K. Teth, G. Fazekas, M. Fridkin and I. Pecht. Characterizing immunodominant and protective influenze hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. Eur. J. Immunol. 27, 3105 (1997).

R. Shainkin-Kestenbaum, S. Zimlichman, M. Lis, L. Preciado-Patt, M. Fridkin and J. Berenheim. Modulation of prostaglandin I2 production from bovine aortic endothelial cells by serum amyloid A and its N-terminal tetradecapeptide. Biomed. Pept. Prot. & Nucleic Acids 2, 101 (1997).

T.W. Moody, J. Leyton, T. Coelho, S. Jakowlew, K. Takahashi, F. Jameison, M. Koh, M. Fridkin, I. Gozes and M. Knight. (Stearyl, Norleucine17) VIP hydride antagonizes VIP receptors on non-small cell lung cancer cells. Life Sciences 61, 1657 (1997).

Y. Katz-Levi, M. Paas-Rozner, S. Kirshner, M, Dayan, E. Zisman, M. Fridkin, I., Wirguin, M. Sela and E. Mozes. A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc. Natl. Acad. Sci. U.S.A. 94, 3200 (1997).[read online]

R. Hershkovitz, L. Preciado-Patt, O. Lider, M. Fridkin and Y.A. Mekori. Mast cell adhesion to extracellular matrix: Local effects of acute phase reactants. Int. Arch. Allergy Immunol. 113, 295 (1997).

R. Granoth, E. Vadai, Y. Burstein, M. Fridkin and E. Tzehoval. Tuftsin-THF-gamma-2 chimeric peptides: potential novel immunomodulators. Immunopharmacol. 37, 43 (1997).[read online]

I. Gozes, G. Lilling, A. Davidson, A. Bardea, A. Reshef, R. Glazer, R. Zomostiano, O. Ashur-Fabian, A. Ticher, I.E. Ashkenazi, S. Rubinraut, M. Fridkin and D.E. Brenneman. Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function and the biological clock. Ann. N.Y. Acad. Sci. 805, 159 (1996).

L. Preciado-Patt, R. Hershkovitz, M. Fridkin and O. Lider. Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T-cells. J. Immunol. 156, 1189 (1996).

L. Preciado-Patt and M. Fridkin. Inhibition by serum amyloid A and its related peptides of cell adhesion to extracellular matrix components. In: Peptides in Immunology. Schneider, C.H. Ed. 1996 European Peptide Society and John Wiley & Sons, Ltd. p. 235 (1996).

L. Preciado-Patt and M. Fridkin. Serum amyloid A (SAA) and corresponding peptides inhibit T-cell adhesion to laminin and bind to human neutrophils. In: Peptides: Chemistry, Structure and Biology. Kaumaya, P.T.P. and Hodges, R.S. Eds. Mayflower Scientific Ltd. p. 786 (1996).

E. Zisman, Y. Katz-Levy, M. Dayan, S.L. Kirshner, M. Paas-Rozner, A. Karni, O. Abramsky, C. Brautbar, M. Fridkin, M. Sela and E. Mozes. Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Proc. Natl. Acad. Sci. U.S.A. 93, 4492 (1996).[read online]

O. Nir, M. Fridkin and Y. Segall. Synthesis of stable spirooxyphosphoranes - potential promoters of catalytic antibodies. Phosphorous, Sulfur and Silicon 241, 109 (1996).

E.J. Yavin, L. Yan, D.M. Desiderio and M. Fridkin. Synthetic peptides derived from the sequence of human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and human cathepsin G. Int. J. Pept. Prot. Res. 48, 465 (1996).

S.L. Kirshner, E. Zisman, M. Fridkin, M. Sela and E. Mozes. Altered peptide ligands of a myastenogenic epitopes on modulators of specific T-cell response. Scand. J. Immunol. 44, 512 (1996).

I. Gozes, Y. Nesher, G. Lilling, M. Fridkin, S. Rubinraut, D.E. Brenneman, T.W. Moody and C. Chaimof. Inhibition of colon cancer growth by VIP antagonism through a cancer-associated VIP receptor. In: Collegium Internationale Chirurglae Digestivae, J.P. Kim and R.E. Condon, Eds. Monduzzi Editore, 1996, pp. 819-821.

H. Zia, T. Hida, S. Jakowlew, M. Birrer, Y. Gozes, J.G. Reubi, M. Fridkin, I. Gozes and T.W. Moody. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56, 3486 (1996).

E. Gershonov, R. Granoth, E. Tzehoval, Y. Gaoni and M. Fridkin. 1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs. J. Med. Chem. 39, 4833 (1996)

L. Preciado-Patt, M. Pras and M. Fridkin. Binding of human serum amyloid (hSAA) and its high density lipoprotein3 complex (hSAA.HDL3) to human neutrophils. Possible implication to the function of a protein of an unknown physiological role. Int. J. Pept. Prot. Res. 48, 503 (1996)

S. Rahimipour, L. Weiner, M. Fridkin, P.B. Shrestha-Dawadi and S. Bitner. Novel naphthoquinonyl derivatives: potential structural components for the synthesis of cytotoxic peptides. Lett. in Pept. Sci. 3, 263 (1996).

P. Shretstha,-Dawadi, S. Bittner, M. Fridkin and S. Rahimipour. On the synthesis of naphthoquinonyl heterocyclic amino acids. Synthesis 1468 (1996)

I. Gozes, A. Bardea, A. Reshef, R. Zamostiano, S. Zhukovosky, S. Rubinraut, M. Fridkin and D.E. Brenneman, Neuroprotective strategy for Alzheimer's disease: intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA 93, 427 (1996).[read online]

R. Philosof-Oppenheimer, I. Pecht and M. Fridkin, The 2,4-dinitrophenyl group for protection of hydroxyl function of tyrosine during solid phase peptide synthesis. Int. J. Pep. Prot. Res. 45, 116 (1995).

I. Gozes, G. Lilling, R. Glazer, A. Ticher, I.E. Ashkenazi, A. Davidson, S. Rubinraut, M. Fridkin and D.E. Brenneman, Surperactive lipophilic peptides discriminate multiple VIP receptors. J. Pharmacol. Exp. Therap. 273, 161 (1995).

S. Konen-Weisman, M. Fridkin and I.R. Cohen, Self and foreign hsp60 T-cell epitope peptides serve as immunogenic carriers for T-cell independent sugar antigens. J. Immunol. 154, 5977 (1995).

D. Leibovitz, Y. Koch, M. Fridkin, F. Pitzer, P. Zwickl, A. Dantes, W. Baumeister and A. Amsterdam, Archeabacterial and eukaryotic proteasomes prefer different sites in cleaving gonadotropin releasing hormone(GnRH). J. Biol. Chem. 270, 11029 (1995).[read online]

I. Gozes, M. Fridkin and D.E. Brenneman, Stearyl-Nle17-VIP: a non-invasive impotence drug and a potent neuro-protectant. Drugs of the Future 20, 680 (1995).

E.J. Yavin, O. Rosen, M. Pontet, E.G. Shephard and M. Fridkin, Proteolysis of human C-reactive protein by neutrophil-derived lysosomal enzymes generates peptides which modulate neutrophil function: Implication to the anti-inflammatory mechanism. Lett. in Peptide Science 2, 7 (1995).

G. Lilling, Y. Wollman, M.N. Goldstein, S. Rubinraut, M. Fridkin, D.E. Brenneman and I. Gozes, Inhibition of human neuroblastoma growth by a specific VIP antagonist. J. Mol. Neuroscience 5, 231 (1995).

O. Mandelboim, E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke and L. Eisenbach, Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nature Medicine 1, 1179 (1995).

I. Gozes, M. Fridkin and D.E. Brenneman, A VIP hybrid antagonist: from development neurobiology to clinical applications. Cell. Molec. Neurobiol. 15, 675 (1995).


This file was last modified on .

Return to Organic Chemistry Home Page